1. Japan Stocks

  2. •

    Health technology

  3. •

    Medical specialties
NIPRO Corporation

NIPRO Corporation

7.40
EUR
+0.05
(+0.68%)
Nov 10Next Earn
NIPRO Corporation
HAN:5FA
(Hannover Stock Exchange)

Recent

price

7.40

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
JPY
1,544.74
1,631.99
1,413.23
1,912.07
2,110.32
2,161.07
2,142.3
2,377.96
2,588.58
2,713.21
2,793.18
3,033.73
3,342.81
3,597.79
3,953.49
4,050.1
- -
Revenue per Share
19.35
35.29
59.99
18.19
80.95
116.22
67.57
71.14
73.68
-75.3
87.12
82.5
28.04
68.11
31.36
82.8
- -
Basic EPS, GAAP
171.86
119.2
132.48
137.02
181.64
176.43
199.35
246.85
251.1
228.37
405.24
418.24
63.74
447.2
419.9
335.13
- -
Free Cash Flow per Basic Share
23.95
21.2
23.43
32.03
32.37
31.6
24.25
39
30.03
22.47
10.55
32.03
26.04
18.55
27.04
23.06
- -
Dividend per Share
839.69
643.94
703.47
832.13
988.78
977.64
999.52
1,037.25
990.13
912.23
987.29
1,135.76
1,265
1,426.55
1,547.83
1,680.71
- -
Book Value per Share
732.74
531.65
502.55
552.05
727.11
713.12
735.7
760.88
748.57
707.44
804.56
934.59
1,056.51
1,211.1
1,330.14
1,363.66
- -
Tangible Book Value per Share
127
130
171
157
154
170
168
166
165
163
163
163
163
163
163
163
163
Basic Weighted Avg Shares
195,942
212,013
241,020
300,752
325,084
366,650
359,699
395,397
426,399
442,516
455,559
494,789
545,199
586,785
644,586
660,538
- -
Sales/Revenue/Turnover
8.79
7.46
4.72
4.09
5.1
6.6
8
6.85
5.59
5.97
6.06
4.83
3.25
3.81
4.13
5.7
- -
Operating Margin (%)
22,987
24,232
24,043
29,978
33,504
33,833
34,035
35,996
38,624
41,825
42,626
46,164
48,743
58,872
65,648
63,737
- -
Depreciation Expense
2,455
4,585
10,231
2,861
12,470
19,718
11,346
11,829
12,136
-12,281
14,209
13,455
4,574
11,109
5,113
13,504
- -
Net Income, GAAP
62.16
54.48
41.2
75.94
35.64
25.89
36.67
27.76
44.07
- -
14.16
35.18
64.63
36.68
65.05
46.58
- -
Effective Tax Rate (%)
1.25
2.16
4.24
0.95
3.84
5.38
3.15
2.99
2.85
-2.78
3.12
2.72
0.84
1.89
0.79
2.04
- -
Profit Margin (%)
40,620
61,346
74,216
45,405
71,945
115,970
134,983
177,903
168,676
143,626
149,867
125,466
186,379
157,691
223,873
166,295
- -
Working Capital
179,635
190,294
228,993
224,346
229,340
271,407
314,265
383,061
390,546
370,610
397,384
402,210
448,730
440,281
468,247
406,230
- -
LT Debt
109,037
113,950
128,762
135,958
178,808
175,505
176,405
183,484
171,829
161,235
174,051
199,866
242,173
269,787
311,620
334,771
- -
Total Equity
1.1
1.7
1.42
0.57
1.9
3.01
2.91
2.87
1.86
- -
3.32
2.07
0.77
1.6
1
2.07
- -
Return on Invested Capital (%)
0.83
1.35
2.54
0.69
2.67
3.93
2.17
2.06
2.01
- -
2.37
1.96
0.6
1.62
0.68
1.71
- -
Return on Capital (%)
2.22
4.24
8.9
2.33
8.51
11.82
6.83
6.98
7.26
-7.92
9.17
7.77
2.34
5.06
2.11
5.13
- -
Return on Common Equity (%)

Capital Structure

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
ST Debt
216,398
234,821
- -
LT Borrowings
401,913
382,651
- -
LT Finance Leases
23,725
23,579
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
163
163
166
Market Capitalization
- -
- -
- -

Working Capital

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
Total Current Assets
580,481
594,832
- -
Cash, Cash Equivalents & STI
109,969
97,835
- -
Accounts Receivable, Net
152,670
175,740
- -
Inventories
257,731
263,976
- -
Total Current Liabilities
387,805
428,537
- -
Payables & Accruals
- -
- -
- -
ST Debt
216,398
234,821
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.03%
14.07%
7.43%
Free Cash Flow
59.65%
98.76%
-20.16%
Net Income, GAAP
-27.08%
36.34%
164.11%
Sales/Revenue/Turnover
6.13%
7.75%
2.47%
Total Cash Common Dividend
11.98%
37.46%
-14.68%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
644,586
2026
- -
- -
- -
- -
660,538
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
31.36
2026
- -
- -
- -
- -
82.8
2027
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
27.04
2026
- -
- -
- -
- -
23.06
2027
- -
- -
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Nipro Corporation (8086.T), a Japan-based multinational medical equipment manufacturer founded on July 8, 1954, and headquartered at 3-26, Senriokashinmachi, Settsu, Osaka, 566-8510, Japan, primarily engages in the development, manufacturing, and sale of disposable medical devices, pharmaceuticals, and pharmaceutical packaging solutions across three main segments; the Medical Devices segment offers products for renal care including dialysis machines such as DIAMAX™ WOW single patient dialysis systems, intervention and anesthesiology tools, injection and infusion devices, cardiopulmonary support equipment, diabetic care solutions like blood glucose monitors, and cell culture products; the Pharmaceuticals segment provides combination products such as dual chamber bags, pre-filled syringes, half-type kits, and contract manufacturing services for injectables, orally administered drugs, and external preparations; while the Pharma Packaging segment supplies glass vials, ampoules, syringes, cartridges, glass tubes, rubber plugs, and glass forming machinery for pharmaceuticals, food, and cosmetics. The company operates globally with subsidiaries and production sites in Japan, the United States, Europe including Sweden via inheritance of Gambro's dialysis legacy, Asia such as China and the Republic of Korea, North and South America, targeting hospitals, home care providers, pharmaceutical companies, and biotech firms with a consolidated workforce of approximately 39,168 employees as of March 31, 2025. Recent developments include the October 2025 acquisition of shares in G2/Spryte Holdco, LLC to establish it as a subsidiary with its US affiliate Spryte Medical receiving FDA IDE approval in November 2025 for the INSYTE pivotal trial of the nOCT imaging system for brain aneurysm treatment; a June 2025 strategic partnership with Samsung Bioepis for biosimilars commercialization in Japan; an August 2025 commercial collaboration between US affiliate Gentuity LLC and GE Healthcare; the January 2025 international launch of DIAMAX™ WOW dialysis machines; multiple trade name changes such as Nipro Americas Group in August 2025, a US medical device subsidiary in January 2025, a Korean medical device subsidiary in April 2025, and a medical software subsidiary in October 2025; a July 2024 announcement of plant site acquisition in the USA for medical device manufacturing; and a 2024 strategic cooperation with Haselmeier to distribute the PiccoJect autoinjector exclusively in Japan.